Jeronimo Martins: Upside Or Persistent Weakness, I Look At 2026-2028E

Jerónimo Martins remains rated Buy at €17.90 per share, but the price target was cut to €18.50 as earnings growth has trailed expectations. Margin recovery and strong volumes at Biedronka and Ara are positive, but deflation and elevated CapEx are keeping EPS growth subdued. The revised valuation assumes normalized EPS of €1.25 and a lower-confidence fair multiple of 14–14.5x P/E.

Analysis

The key underwriting issue is not volume but the conversion of volume into free cash flow. JMT’s Polish and Colombian banners can sustain traffic gains while still disappointing EPS if food deflation limits ticket growth and labor, logistics, and store-opening costs remain sticky. That combination typically delays operating leverage by 2-4 quarters, leaving consensus vulnerable to further modest EPS cuts even if reported sales remain resilient.

CapEx is the more consequential valuation constraint than the revised earnings assumption. Expansion spending can be strategically rational, but it reduces near-term cash returns and raises the required confidence in new-store maturity curves; a 14-14.5x normalized P/E is not obviously cheap if FCF conversion remains depressed. Relative to defensive European food retail peers, JMT needs demonstrable improvement in cash generation—not just margin percentage—to earn multiple expansion over the next 6-18 months.

Near term, the stock is likely range-bound: improved gross margin can support results over the next 1-3 months, but investors will focus on whether management can protect EBITDA while moderating CapEx intensity. The contrarian upside is that prolonged Polish food deflation could eventually become a margin tailwind as procurement costs reset faster than shelf prices; however, competitive reinvestment by discount peers would capture much of that benefit. The thesis is falsified by another guidance reset, CapEx remaining elevated without sales-density improvement, or evidence that Biedronka must reinvest gross-margin gains into price to defend share.

Key Decisions for Investors

• Maintain JMT as a watch-list long rather than add aggressively before the next results: require evidence of improving operating cash flow and stable CapEx-to-sales. A constructive entry is more compelling only if the shares trade below roughly 13x normalized €1.25 EPS, providing a clearer margin of safety against another earnings revision.
• For a 1-3 month tactical position, buy JMT only on post-results weakness if management reiterates EBITDA-margin and cash-flow objectives; target a re-rating toward 14.5x normalized earnings, with risk controlled by exiting on a material reduction in full-year EBIT/EBITDA guidance.
• Consider a relative-value screen versus Ahold Delhaize (AD.AS) and Carrefour (CA.PA): JMT should outperform only if its volume-led growth translates into superior FCF conversion. If cash conversion fails to improve while peers maintain payouts and buybacks, favor long AD.AS / short JMT as a defensive retail pair.
• Monitor Polish food CPI, wage inflation, and Biedronka same-store sales monthly. Disinflation accompanied by stable gross margin is the upside catalyst; renewed wage acceleration or price-led competitive intensity would make current normalized-EPS assumptions too optimistic.